Palbociclib unlikely to meet primary endpoint in early breast cancer trial

Following a pre-planned efficacy and futility analysis of data, an independent Data Monitoring Committee concluded the drug is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival.

Source:

PharmaTimes